25 July 2018 in BMC Cancer
Bladder cancer often recurs due to incomplete elimination of the cancer stem cells (CSCs). Therefore, new strategies targeting bladder CSCs are needed and the aim of this study was to investigate the effect of S100A4 on the proliferation capacity of MB49 bladder cancer stem cells (MCSCs). MCSCs were established and validated. The expression level of S100A4 in MCSCs and MB49 cells was evaluated using Western blotting and quantitative polymerase chain reaction (QPCR). S100A4 was overexpressed or knocked-down by transfection of pCMV6-XL5-S100A4 plasmid or RNA interference (RNAi) respectively. Proliferation capacity of MCSC was evaluated by cell proliferation assay and in vivo tumorigenicity study. Transcriptional activity of nuclear factor kappa B (NF-κB) was analyzed using luciferase reporter assay, and the level of interleukin (IL)-2 as well as tumor necrosis factor (TNF) was quantified by QPCR. Protein-protein interaction of S100A4 and inhibitor of nuclear factor kappa B NF-κB kinase (IKK) was analyzed by immunoprecipitation. S100A4 was significantly up-regulated in MCSCs, which positively associated with the proliferation capacity, as well as the level of NF-κB, IKK, IL-2 and TNF in MCSCs. Knock-down of S100A4 could reverse such effects. Using immunoprecipitation assay, an interaction between S100A4 and IKK could be observed. S100A4 is upregulated in MCSCs and possibly enhance the proliferation ability of MCSCs by way of activating the IKK/NF-κB signaling pathway, and S100A4 maybe a hopeful therapeutic target for MCSCs.
23 October 2020 in Reproductive Sciences
1 January 2023 in Analytical Cellular Pathology
Background. Nonobstructive azoospermia (NOA) is a complex disease characterized by the spermatogenic dysfunction of testicular tissues. The roles played by long noncoding RNAs (lncRNAs) in NOA pathogenesis have not been extensively studied. Methods. Microarray assays were performed on samples of testicular biopsy tissue obtained from patients with NOA for the purpose of identifying differentially expressed lncRNAs and messenger RNA (mRNA) transcripts, and the results were verified by quantitative real‐time polymerase chain reaction. Mouse‐derived GC‐1 spermatogonia (spg) cells undergoing treatment with Adriamycin (ADR) were used to investigate the biological functions of the selected lncRNAs in vitro. The target microRNAs (miRNAs) of lncRNAs and the target mRNAs of miRNAs were predicted by a bioinformatics analysis. Functional studies performed using the CCK‐8 assay, EdU incorporation assay, apoptosis detection, and senescence‐associated β‐galactosidase (SA‐β‐Gal) staining were conducted using GC‐1 spg cells. Results. Totals of 2,652 lncRNAs and 2,625 mRNAs were found to be differentially expressed in the testicular tissue of NOA patients when compared with patients in a control group. Dynamin 3 opposite strand (DNM3OS) was a provider of pe‐miR‐214‐5p that positively regulates miR‐214‐5p expression in GC‐1 spg cells. The E2 factor (E2F) family of transcription factor 2 (E2F2) was initially predicted and subsequently verified to be a downstream gene of miR‐214‐5p. E2F2 expression was upregulated after DNM3OS knockdown in ADR‐treated GC‐1 spg cells. Moreover, knockdown of either DNM3OS or miR‐214‐5p significantly alleviated ADR‐induced decreases in cellular activity and proliferation, as well as increases in apoptosis and senescence of mouse spermatogonial GC‐1 spg cells. Conclusions. DNM3OS was found to regulate the apoptosis and senescence of spermatogonia by providing miR‐214‐5p and decreasing E2F2 expression, suggesting it as a novel target for gene therapy of male infertility.
29 July 2026 in SSRN Electronic Journal
Background: Early-onset preeclampsia (EOPE) is frequently complicated by fetal growth restriction (FGR). The sFlt-1/PlGF ratio reflects maternal angiogenic imbalance but provides limited insight into placental pathology-the root cause of preeclampsia. Collagen XVIIA1 (COLXVIIA1), a transmembrane hemidesmosomal collagen expressed in trophoblasts, may serve as a biomarker of placental injury. Methods: Circulating COLXVIIA1 was first measured in gestational age–matched peripheral blood samples from EOPE and normotensive pregnancies (n = 6 per group). Placental origin was assessed using paired uterine and peripheral vein samples (n = 9). Placental COLXVIIA1 expression, localisation, and processing were analysed in normotensive and EOPE placentas. Trophoblast-derived extracellular vesicles (TB-sEVs) were isolated from ex vivo perfused placentas to assess COLXVIIA1 packaging. In a prospective cohort of 167 women with suspected preeclampsia, circulating COLXVIIA1 was analysed alongside PlGF and sFlt-1, and diagnostic performance of the COLXVIIA1/PlGF ratio was compared with sFlt-1/PlGF. Findings: Circulating COLXVIIA1 levels were significantly elevated in EOPE compared with gestational age–matched controls, indicating independence from gestational age. Uterine vein levels exceeded peripheral levels, consistent with placental release. COLXVIIA1 expression was localised to trophoblasts and amniotic epithelium. In EOPE placentas, COLXVIIA1-enriched hotspots co-localised with fibrin nodules, perivillous fibrin deposition, and peri-infarct regions. Increased proteolytic processing (∼120 kDa ectodomain) and preferential packaging of transmembrane COLXVIIA1 into TB-sEVs were observed. The COLXVIIA1/PlGF ratio performed comparably to sFlt-1/PlGF for overall preeclampsia and showed strong predictive accuracy for EOPE with FGR (AUC = 0.858), confirmed by bootstrap analysis. Interpretation: Abnormal COLXVIIA1 expression, processing and release reflects trophoblast response to structural injury and provides a circulating signal complementary to angiogenic markers. The COLXVIIA1/PlGF ratio captures a distinct dimension of placental pathology and may improve risk stratification in EOPE, particularly in pregnancies complicated by FGR.